Adial Pharmaceuticals
CHARLOTTESVILLE, VA, United States · Biotechnology, Healthcare, Health Care · 17 employees
Adial Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development of therapies for the treatment and prevention of addiction and related disorders. The Company’s lead investigational new drug product, AD04, is a genetically targeted, serotonin-3 receptor antagonist, therapeutic agent for the treatment of Alcohol Use Disorder (AUD) in heavy drinking patients and was rec
Funding history
- Funding Round — $4.3M — Dec 2025
- Funding Round — $4.8M — May 2025
- Series seed — $288K — Mar 2024
- Series seed — $4.0M — Oct 2023
- Series pre-seed — $53K — Jun 2023
Recent signals
- Jun 11, 2026: Acquired Adial Pharmaceuticals acquires Azora Therapeutics
- Dec 03, 2025: Raised $4.3M
- May 14, 2025: Raised $4.8M
- Jan 29, 2025: Launched Adial Pharmaceuticals announces completion of the AD04 pharmacokinetics study results, aimed at treating Alcohol Use Disorder in patients with a specific genomic biomarker.
- Nov 05, 2024: Adial Pharmaceuticals Appoints Vinay Shah as Chief Financial Officer
- Aug 13, 2024: Adial Pharmaceuticals Signs Agreement with Boudicca Dx to Advance Regulatory Strategy for Companion Diagnostic Genetic Test for AD04
- Mar 14, 2024: Raised $288K in Series seed
- Jan 18, 2024: Adial Announces Appointment of Tony Goodman as Chief Operating Officer
See plans & pricing → Track Adial Pharmaceuticals’s funding, hiring, and signals — with verified contacts — on Fundz.